The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switchin...
The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept
About this item
Full title
Author / Creator
Publisher
London: BMJ Publishing Group Ltd and European League Against Rheumatism
Journal title
Language
English
Formats
Publication information
Publisher
London: BMJ Publishing Group Ltd and European League Against Rheumatism
Subjects
More information
Scope and Contents
Contents
Objective The aim of this study was to test the hypothesis that the reason for non-response (caused by immunogenicity or not) to a first tumour necrosis factor (TNF) inhibitor defines whether a second TNF inhibitor will be effective. Methods This cohort study consisted of 292 consecutive patients with rheumatoid arthritis (RA), all treated with eta...
Alternative Titles
Full title
The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_840353468
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_840353468
Other Identifiers
ISSN
0003-4967
E-ISSN
1468-2060
DOI
10.1136/ard.2010.135111
